Acute Coronary Syndromes

Acute coronary syndrome (ACS) is most commonly caused by a heart attack (myocardial infarction) where blood flow to the heart is suddenly blocked. This is usually caused by a blood clot from a ruptured coronary artery atherosclerotic plaque. Other causes include spontaneous coronary artery dissection (SCAD), which most commonly occurs in women. ACS is usually treated in a cath lab with angioplasty and the placement of a stent to prop the vessel open.

RSS icon

FDA provides next steps in wake of blood test recall

According to the FDA, a limited number of unaffected blood tests are available if providers are unable to identify a better way forward. 

FDA announces Class I recall of nearly 8,000 heart attack tests due to inaccurate results

Overall, the recall includes 7,799 blood tests intended to help physicians identify early signs of a myocardial infarction. 

Heart failure symptoms after PCI increase risk of adverse events

Researchers in Japan tracked BNP levels and bleeding events among more than 7,000 PCI patients. The group noted that managing heart failure in the first 30 days after PCI can help boost outcomes. 

AI artificial intelligence stethoscope doctor

AI model outperforms researchers’ ‘wildest dreams’ with accurate heart attack assessments

The algorithm, developed using data from more than 7,00 chest pain patients, performed better than multiple techniques currently used to evaluate cardiac events. 

Colchicine Lodoco Agepha Pharma price cost

What will Lodoco cost? Looking ahead after FDA’s historic approval of colchicine for CVD

“Our pricing strategy for Lodoco is focused on helping to ensure access to as many people as possible,” an executive with Agepha Pharma told Cardiovascular Business. 

The U.S. Food and Drug Administration (FDA) priority review, the FDA has cleared the Agepha Pharma USA LLC's drug Lodoco (colchicine) as the first anti-inflammatory atheroprotective cardiovascular treatment.

Cardiologists applaud FDA’s approval of colchicine for CVD

"The FDA's approval of colchicine confirms that we are entering a new era of patient care," said one veteran cardiologist familiar with the drug. 

The U.S. Food and Drug Administration (FDA) priority review, the FDA has cleared the Agepha Pharma USA LLC's drug Lodoco (colchicine) as the first anti-inflammatory atheroprotective cardiovascular treatment.

FDA approves colchicine, the first anti-inflammatory drug for treating cardiovascular disease

The FDA's approval of colchicine, which is marketed and sold under the name Lodoco, is expected to have a big impact on cardiac care and outcomes.

healthcare value value-based care money dollar

Bitterroot Bio, a new biotech company launched by physicians and industry veterans, raises $145M

The new company formed in 2021, but waited until now to publicly launch. Its founders included two Stanford University physicians.

Displaying 161 - 168 of 594
Design by Adaptive Theme